This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -14.89% and 36.41%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Cytokinetics (CYTK) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
by Zacks Equity Research
Key highlights of the past week are multiple study failures and other pipeline updates.
Amgen Starts Phase III Enrollment for Heart Failure Drug
by Zacks Equity Research
Amgen (AMGN) and partners started enrollment for the second phase III study of omecamtiv mecarbil, which is being developed for the potential treatment of heart failure with reduced ejection fraction.
Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of 12.73% and 171.40%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Tiny Biotech Stocks With Superb Growth Potential
by Swarup Gupta
A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.
Cytokinetics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Cytokinetics has been struggling lately, but the selling pressure may be coming to an end soon.
Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of 24.53% and 377.18%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Q3 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics (CYTK) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Cytokinetics (CYTK) Stock?
by Zacks Equity Research
Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.
Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks
by Arpita Dutt
FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.
Is the Options Market Predicting a Spike in Cytokinetics (CYTK) Stock?
by Zacks Equity Research
Investors need to pay close attention to Cytokinetics (CYTK) stock based on the movements in the options market lately.
Implied Volatility Surging for Cytokinetics (CYTK) Stock Options
by Zacks Equity Research
Cytokinetics (CYTK) needs Investors to pay close attention to the stock based on moves in the options market lately.
Options Traders Expect Huge Moves in Cytokinetics (CYTK) Stock
by Zacks Equity Research
Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.
New Strong Sell Stocks for May 4th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) reported a loss of 39 cents per share (excluding restructuring charge) in the three month transition period ended Dec 31, marginally wider than both the Zacks Consensus Estimate and the year-ago loss of 38 cents.
Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) posted fourth-quarter 2016 loss of $1.34 per share, narrower than the Zacks Consensus Estimate of a loss of $1.55 but wider than the year-ago loss of $1.08.
Kura Oncology (KURA) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
Kura Oncology (KURA) saw its shares rise almost 7% in the last trading session.
Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) reported loss of 7 cents per share in the fourth quarter of 2016 (including the impact of stock-based compensation expenses), narrower than the Zacks Consensus Estimate of a loss of 18 cents.